X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
Enter email and you're done. No subscription, no credit card.
Search, tap and you're done. Over 3,400 medicines.
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
You read the package leaflet and your condition is not in it. That is usually not an oversight but a deliberate decision: off-label use means that an authorised medicine is used outside its approved indication — for a different condition, at a different dose or in a different age group. It is neither forbidden nor disreputable, and in some specialties it is simply the norm. What you should know: who pays, who carries the responsibility and which five questions you can ask at your appointment.
Record what you take and what for — including the prescriptions the package leaflet does not mention.
Every medicine is authorised for one particular purpose. The authorisation states which condition the substance may be used for, at what dose, in which pharmaceutical form and for which age group. If a prescription departs from any one of those four points, it is called off-label use — literally: outside the label.¹
The order of things matters here: the medicine itself is authorised and tested. What was not examined in the authorisation procedure is the particular use that concerns you. That is a fundamental difference — and the reason why off-label use has nothing to do with experiments or grey areas.
The commonest misconception runs: if a medicine is not authorised for a condition, it presumably does not work there either. The connection is a different one — and it is above all economic.
An authorisation has to be applied for, and that is done by the manufacturer. The application requires extensive clinical trials, which cost a great deal of money and take years. For an indication with a few thousand people affected, or for a substance whose patent protection expired long ago, that effort pays off for no company. The result: the use is never applied for — not even when the scientific evidence is good.
So the rule is: the absence of an authorisation says something about the application, not automatically about the evidence. There are off-label uses that have been recommended in the guidelines of the medical societies for decades and have been studied in large trials. And there are others for which little more speaks than anecdotal reports. Because of that range, asking is worthwhile — rather than blanket trust or blanket rejection.
In three areas, use outside the authorisation is not the exception but the rule. Knowing that makes a prescription of this kind far easier to take in your stride.
Authorisation trials involving children are difficult for good reasons: they are ethically sensitive, organisationally demanding and have to be carried out separately for several age groups. As a result, many substances carry an authorisation for adults only, even though the medicine has been used in children for decades. Paediatricians then work with established, age-adjusted dosing recommendations from the professional societies and with specialised paediatric formularies.² What else to bear in mind when giving medicines to children is covered in the guide Medications for children.
In cancer treatment, knowledge develops faster than authorisations can follow. A substance may be authorised for one tumour type but also show an effect in another tumour with the same genetic change. Years pass before the authorisation is extended — often too long. Off-label prescriptions are usually discussed and documented here in a tumour board.
With conditions affecting very few people, the trial base for a regular authorisation is simply not there. Treatment then rests on registries, international treatment recommendations and the experience of specialist centres.
Off-label use sounds like specialist medicine. In fact it concerns very ordinary prescriptions from the GP practice.
| Substance | Originally authorised for | Frequently used for | Background |
|---|---|---|---|
| Amitriptyline | Depression | Chronic pain, tension-type headache | At a low dose the substance dampens pain processing — depending on the product this use is covered by the authorisation, depending on the product it is not |
| Beta blockers | High blood pressure, heart conditions | Migraine prevention | Only certain members of the group and certain products are authorised for migraine prophylaxis; others are used off-label |
| Metformin | Type 2 diabetes | Polycystic ovary syndrome (PCOS) | Acts on insulin resistance, which plays a central role in PCOS — there is no authorisation of its own for this in Germany |
Amitriptyline is the textbook case: opening the box and reading "antidepressant" when the problem is back pain is a shock at first. But the low pain dose lies well below the antidepressant dose, and the effect rests on a different mechanism. It is similar with migraine: metoprolol and related beta blockers are among the established options for preventing migraine, even though the pack talks about blood pressure — with some products this use is covered by the authorisation, with others it is not. And metformin is frequently prescribed for PCOS without any authorisation existing for it.
Whether one of these options makes sense for you is always decided by your treating practice — depending on your other conditions, your other medicines and your symptoms.
This is the point at which off-label use really does get complicated in practice. As a rule, the statutory health insurers in Germany reimburse medicines within their authorisation. Outside it, reimbursement is possible but tied to conditions.
The case law of the Federal Social Court (Bundessozialgericht), Germany's highest court in social insurance matters, has set out three requirements that must be met at the same time:³
In addition there is a formal route via the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA): expert groups assess individual off-label uses; those assessed positively are listed in an annex to the Pharmaceuticals Directive and can then be prescribed in the normal way.³ If your use is listed there, the matter is straightforward.
If it is not listed there, it goes through an application for reimbursement in the individual case. In practice that means: the practice writes a detailed medical justification, you submit it with an informal application to your health insurer, the insurer usually obtains an opinion from the Medical Service (Medizinischer Dienst) and then decides.⁴
Some practices offer a private prescription instead. That is legally clean, but it shifts the costs entirely to you. In that case ask for the actual price before you go to the pharmacy — and then ask whether an application to your insurer might have a chance after all.
Previous treatments, intolerances and progress — documented instead of reconstructed from memory.
Within the authorisation, responsibility is shared: the manufacturer is liable for the product and its tested use, the practice for deciding on the indication. With off-label use that shifts — the prescribing practice carries a considerably larger share of the responsibility, because the use departs from the tested framework.
From that follows an extended duty to inform you. Before an off-label prescription, you should have explained to you:
That is why there is often an additional consultation about all this, sometimes with a form to sign. It is not a sign of mistrust and not an indication that anything is particularly risky — it is the documentation of a conversation that has to take place anyway.
An off-label prescription is a good reason for a structured conversation. These five questions cover everything that becomes relevant in practice — write them down before your appointment.
How to prepare well for conversations like this — with a list of questions, an overview of your medicines and notes — is described in the guide Preparing for a doctor's appointment. And because the package leaflet will not mention your use at all, it is worth looking at Understanding the package leaflet beforehand: it explains which sections still apply to you — interactions, contraindications and side effects very much do.
Several terms circulate around off-label use and are often mixed up. The difference matters in practice, because the question of costs hangs on it too.
| Term | What is meant | Status of the medicine |
|---|---|---|
| Off-label use | An authorised medicine used outside its indication, its dose or its age group | Authorised in Germany and regularly on the market |
| Compassionate use (hardship programme) | Access to a medicine that is not yet authorised, for people with a serious condition and no treatment alternative, usually through a manufacturer's programme | Not yet authorised, as a rule already tested in trials |
| Individual healing attempt | Treatment in a single case with a novel or unusual approach, when nothing else is left | Very variable; particularly high requirements for information and documentation |
| Extension of authorisation | The manufacturer applies subsequently for an additional indication | Once approved, the use is regularly authorised — off-label becomes on-label |
In practice that means: with off-label use you collect the medicine from the pharmacy as normal, whereas with compassionate use it is supplied through a programme and usually through a specialist centre. And because an extension of authorisation can turn a self-funded treatment into an insured benefit, with long-term off-label treatments it is worth asking about the authorisation status from time to time.
For every authorised use, the authorities systematically collect suspected side effect reports. It is exactly this data base that is thinner for off-label use: because the use was never part of an authorisation procedure, there is less structured experience of unwanted effects in this particular constellation.
That is why every report counts double. In Germany the Federal Institute for Drugs and Medical Devices (BfArM) and, for vaccines and biomedicinal products, the Paul-Ehrlich-Institut (PEI) receive suspected case reports — and expressly directly from patients too, not only from doctors and pharmacies.⁵ You need no proof for that; a reasonable suspicion is enough.
State in every report that this was an off-label use. That matters for the assessment — and it helps other people with the same condition.
Off-label prescriptions are particularly prone to misunderstandings at the interfaces of the health system. Three typical scenes:
All three cases can be defused with a single habit: note the reason for taking each medicine — and with off-label prescriptions add a note that this is a use outside the authorisation, together with the prescribing practice. How to build such a list and keep it up to date is described in Keeping a medication list.
For people with a long-term condition this is part of the basic kit — together with findings, laboratory values and the course of their symptoms. Further everyday strategies can be found under Chronic illness in everyday life.
The interaction check tests your combination regardless of what you are taking it for.
Here off-label use is, as described, an everyday matter. What counts is precise dosing, usually based on body weight, and a suitable pharmaceutical form. Ask at the pharmacy whether the preparation may be split — not every tablet tolerates that.
Many medicines are not expressly authorised for pregnancy and breastfeeding, even though extensive experience exists — their use is then off-label. An independent assessment is provided by the embryotox advice portal run by the Charité in Berlin. Never stop a medicine here on your own initiative: an untreated condition can be the greater risk.
The more preparations come together, the greater the danger that an off-label prescription is misread or duplicated. A written overview counts for particularly much here — plus a regular medication review at the practice or the pharmacy.
Digital medication plan
Every preparation with the reason for taking it — so an off-label prescription is never a puzzle anywhere again.
Interaction check
Interactions depend on the substance, not on the indication — the check applies to off-label prescriptions in just the same way.
Health history
Documents effects and side effects over time — the basis for the application to your insurer and for the decision on whether the treatment continues.
Medication reminder
With unfamiliar dosing schedules in particular, the reminder makes sure the treatment runs as agreed.
